OptimizeRx (OPRX) Liabilities and Shareholders Equity (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $167.3 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed 0.3% year-over-year to $167.3 million; the trailing twelve-month figure through Mar 2026 stood at $683.8 million (up 1.0% YoY), and the FY2025 full-year result was $176.9 million, up 3.36% from the prior year.
• Liabilities and Shareholders Equity slipped to $167.3 million in Q1 2026, from $176.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $183.4 million in Q4 2023 to a low of $121.3 million in Q2 2023.
• A 5-year average of $156.1 million and a median of $167.3 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity decreased 17.72% in 2023 and jumped 42.49% in 2024, its largest moves.
• Tracing OPRX's Liabilities and Shareholders Equity over 5 years: stood at $134.7 million in 2022, then soared by 36.18% to $183.4 million in 2023, then decreased by 6.66% to $171.2 million in 2024, then gained by 3.36% to $176.9 million in 2025, then slipped by 5.46% to $167.3 million in 2026.
• Business Quant data shows OPRX's Liabilities and Shareholders Equity at $167.3 million in Q1 2026, $176.9 million in Q4 2025, and $170.3 million in Q3 2025.